IDEXX Laboratories Announces Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
IDEXX Labs (IDXX) Tops Q3 EPS by 8c; Raises FY18 EPS Outlook, Maintains FY18 Revenue Guidance, Offers Prelim. FY19 EPS/Revenue Views
November 1, 2018 6:41 AM EDT(Updated - November 1, 2018 6:56 AM EDT)
(Update corrects consensus revenue figure)
IDEXX Labs (NASDAQ: IDXX) reported Q3 EPS of $1.05, $0.08 better than the analyst estimate of $0.97. Revenue for the quarter came in at $545.45 million versus the consensus estimate of $545.49 million.
Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organicDelivers EPS of $1.05, a 33% increase year-over-year on a reported basis or 39% on a comparable constant currency basisRefines 2018 reported revenue guidance to $2,205 billion - $2,215... More